MATRix方案诱导治疗初诊原发性中枢神经系统弥漫大B细胞淋巴瘤:常规实践中的可行性与疗效国际研究
该回顾性研究纳入156例临床试验外接受MATRix方案治疗的初诊PCNSL患者,中位年龄62岁、ECOG 2分,总缓解率79%,治疗相关死亡6%。中位随访27.4个月,2年无进展生存56%、总生存64.1%;不符合IELSG32试验入组标准者剂量强度更低且结局更差。
要点
- MATRix在常规实践中对符合试验标准的初诊PCNSL患者可行且有效
- 不符合IELSG32入组标准者接受更低剂量强度且结局显著更差
- 常规实践中治疗相关死亡率为6%,需关注耐受性
核心结论
- MATRix方案在临床试验外的常规实践中对适合的初诊PCNSL患者可行且有效,符合试验标准者结局与IELSG32试验一致。
研究设计与样本
- 回顾性研究,纳入156例临床试验外接受MATRix方案治疗的初诊PCNSL连续患者。
- 中位年龄62岁(范围28-78岁),中位ECOG体能状态评分2分(范围0-4分)。
主要发现
- MATRix后总缓解率为79%。
- 记录到9例(6%)治疗相关死亡。
- 中位随访27.4个月(95%CI 24.4-31.9%),2年无进展生存率为56%(95%CI 48.4-64.9%),2年总生存率为64.1%(95%CI 56.7-72.5%)。
- 不符合IELSG32试验入组标准的患者接受更低剂量强度且结局显著更差。
临床怎么用
- MATRix可作为适合的初诊PCNSL患者在常规实践中的诱导治疗。
- 对不符合试验入组标准者需谨慎评估剂量强度与耐受性。
局限性
- 回顾性研究设计。
- 仅纳入临床试验外接受MATRix治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). However, nothing is known about its feasibility and efficacy in everyday practice, where patients are more often older/frailer than those enrolled in clinical trials. We conducted a retrospective study addressing tolerability/efficacy of MATRix in 156 consecutive patients with newly diagnosed PCNSL treated outside a clinical trial. Median age and ECOG Performance Status of considered patients were 62 years (range 28-78) and 2 (range 0-4). The overall response rate after MATRix was 79%. Nine (6%) treatment-related deaths were recorded. After a median follow-up of 27.4 months (95% confidence interval [CI] 24.4-31.9%), the two-year progression-free and overall survival were 56% (95% CI 48.4-64.9%) and 64.1% (95% CI 56.7-72.5%) respectively. Patients not eligible for the IELSG32 trial were treated with lower dose intensity and had substantially worse outcomes than those fulfilling inclusion criteria. This is the largest series of PCNSL patients treated with MATRix outside a trial and recapitulates the IELSG32 trial outcomes in the non-trial setting for patients who fit the trial criteria. These data underscore the feasibility and efficacy of MATRix as induction treatment for fit patients in routine practice.
引用
- Schorb E, Fox CP, Kasenda B, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020. PMID: 31997308. doi:10.1111/bjh.16451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。